Clearside Biomedical Funding Round

12/3/2015

Venture Equity

$20,000,000

Series C

Presently, Clearside has three ongoing clinical trials using CLS-TA, Clearside's proprietary formulation of triamcinolone acetonide developed specifically for administration using the SCS� Microinjector. Clearside has initiated the enrollment process in the Phase 3 clinical trial (Peachtree) for the treatment of patients with macular edema associated with non-infectious uveitis. Clearside's Phase 2 trial, Tanzanite, is assessing the efficacy and safety of CLS-TA used concomitantly with an intravitreal injection-delivered VEGF inhibitor in patients with macular edema associated with retinal vein occlusion. Clearside recently completed enrollment of the third trial, Dogwood, a Phase 2 trial evaluating the safety and efficacy of CLS-TA in patients with macular edema associated with non-infectious uveitis.

Publicly-held

Biopharmaceutical

900 North Point Pkwy. 200
Alpharetta, GA 30005
USA

Clearside BioMedical (Nasdaq: CLSD) is an ophthalmic company specializing in the research, development and commercialization of therapeutic products.